Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection
Abstract Objective To assess the efficacy and safety of intravitreal aflibercept injection in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS). Purpose To assess safety of intravitreal aflibercept for the treatment of CNV secondary to presumed ocular histoplasmosis sy...
Gespeichert in:
| Veröffentlicht in: | Canadian journal of ophthalmology 2016-04, Vol.51 (2), p.91-96 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 96 |
|---|---|
| container_issue | 2 |
| container_start_page | 91 |
| container_title | Canadian journal of ophthalmology |
| container_volume | 51 |
| creator | Walia, Harpreet S., MD Shah, Gaurav K., MD Blinder, Kevin J., MD |
| description | Abstract Objective To assess the efficacy and safety of intravitreal aflibercept injection in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS). Purpose To assess safety of intravitreal aflibercept for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome. Methods Masked, open-label, prospective study. Five subjects will receive 2.0 mg aflibercept injection every 8 weeks with 3 initial monthly doses over a 12 month period. Results No adverse systemic or ocular were reported. At month six, the mean visual acuity improved by 7.8 ETDRS letters, mean central subfoveal thickness decreased by 38.8 microns and mean OCT volume decreased by 0.076 mm3 . At month twelve, the mean visual acuity improved by12.4 ETDRS letters, mean central subfoveal thickness decreased by 34.6 microns and mean OCT volume decreased by 0.576 mm3. Conclusion The use of intravitreal 2.0 mg aflibercept injection for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome yielded no systemic or ocular adverse events and produced improvement in visual acuity and reduction of OCT thickness and volume. |
| doi_str_mv | 10.1016/j.jcjo.2015.11.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1782216526</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0008418215004846</els_id><sourcerecordid>1782216526</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-fca1d0a23602aeb33b28c28fab872e13f887053adb1ba57a9d0cbb7b7d28a8f93</originalsourceid><addsrcrecordid>eNp9kc1u1TAUhC0EopfCC7BAXrJJ8LGT2JUQErriT6pgQWFr2c4JdZrEwXaK-vY4uoUFC1ZncWZGmm8IeQ6sBgbdq7Ee3RhqzqCtAWrG5ANyAAltJUTHHpIDY0xVDSh-Rp6kNDImhGy6x-SMS6Za3rUHcnMV0eQZl0zDQI-fv9OELiy9iXc0B7pGTNuMPQ1um0yk1z7lsE4mzSH5RH_5fE39kqO59bkETdQMk7cYHa6Z8prR-Uf5j-iyD8tT8mgwU8Jn9_ecfHv_7ur4sbr88uHT8e1l5RqAXA3OQM8MLx24QSuE5cpxNRirJEcQg1KStcL0FqxppbnombNWWtlzZdRwIc7Jy1PuGsPPDVPWs08Op8ksGLakQSrOoSsAipSfpC6GlCIOeo1-LuU1ML1D1qPeIesdsgbQBXIxvbjP32xh89fyh2oRvD4JsLS89Rh1ch4Xh72PBYXug_9__pt_7G7yi3dmusE7TGPY4lL4adCJa6a_7jPvK0PLWKOaTvwGoamkTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1782216526</pqid></control><display><type>article</type><title>Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Walia, Harpreet S., MD ; Shah, Gaurav K., MD ; Blinder, Kevin J., MD</creator><creatorcontrib>Walia, Harpreet S., MD ; Shah, Gaurav K., MD ; Blinder, Kevin J., MD</creatorcontrib><description>Abstract Objective To assess the efficacy and safety of intravitreal aflibercept injection in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS). Purpose To assess safety of intravitreal aflibercept for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome. Methods Masked, open-label, prospective study. Five subjects will receive 2.0 mg aflibercept injection every 8 weeks with 3 initial monthly doses over a 12 month period. Results No adverse systemic or ocular were reported. At month six, the mean visual acuity improved by 7.8 ETDRS letters, mean central subfoveal thickness decreased by 38.8 microns and mean OCT volume decreased by 0.076 mm3 . At month twelve, the mean visual acuity improved by12.4 ETDRS letters, mean central subfoveal thickness decreased by 34.6 microns and mean OCT volume decreased by 0.576 mm3. Conclusion The use of intravitreal 2.0 mg aflibercept injection for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome yielded no systemic or ocular adverse events and produced improvement in visual acuity and reduction of OCT thickness and volume.</description><identifier>ISSN: 0008-4182</identifier><identifier>EISSN: 1715-3360</identifier><identifier>DOI: 10.1016/j.jcjo.2015.11.007</identifier><identifier>PMID: 27085265</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Aged ; Angiogenesis Inhibitors - administration & dosage ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - microbiology ; Eye Infections, Fungal - drug therapy ; Eye Infections, Fungal - microbiology ; Female ; Fluorescein Angiography ; Histoplasmosis - drug therapy ; Histoplasmosis - microbiology ; Humans ; Internal Medicine ; Intravitreal Injections ; Male ; Middle Aged ; Ophthalmology ; Prospective Studies ; Receptors, Vascular Endothelial Growth Factor - administration & dosage ; Recombinant Fusion Proteins - administration & dosage ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity - physiology</subject><ispartof>Canadian journal of ophthalmology, 2016-04, Vol.51 (2), p.91-96</ispartof><rights>Canadian Ophthalmological Society</rights><rights>2016 Canadian Ophthalmological Society</rights><rights>Copyright © 2016 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-fca1d0a23602aeb33b28c28fab872e13f887053adb1ba57a9d0cbb7b7d28a8f93</citedby><cites>FETCH-LOGICAL-c411t-fca1d0a23602aeb33b28c28fab872e13f887053adb1ba57a9d0cbb7b7d28a8f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0008418215004846$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27085265$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walia, Harpreet S., MD</creatorcontrib><creatorcontrib>Shah, Gaurav K., MD</creatorcontrib><creatorcontrib>Blinder, Kevin J., MD</creatorcontrib><title>Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection</title><title>Canadian journal of ophthalmology</title><addtitle>Can J Ophthalmol</addtitle><description>Abstract Objective To assess the efficacy and safety of intravitreal aflibercept injection in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS). Purpose To assess safety of intravitreal aflibercept for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome. Methods Masked, open-label, prospective study. Five subjects will receive 2.0 mg aflibercept injection every 8 weeks with 3 initial monthly doses over a 12 month period. Results No adverse systemic or ocular were reported. At month six, the mean visual acuity improved by 7.8 ETDRS letters, mean central subfoveal thickness decreased by 38.8 microns and mean OCT volume decreased by 0.076 mm3 . At month twelve, the mean visual acuity improved by12.4 ETDRS letters, mean central subfoveal thickness decreased by 34.6 microns and mean OCT volume decreased by 0.576 mm3. Conclusion The use of intravitreal 2.0 mg aflibercept injection for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome yielded no systemic or ocular adverse events and produced improvement in visual acuity and reduction of OCT thickness and volume.</description><subject>Aged</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - microbiology</subject><subject>Eye Infections, Fungal - drug therapy</subject><subject>Eye Infections, Fungal - microbiology</subject><subject>Female</subject><subject>Fluorescein Angiography</subject><subject>Histoplasmosis - drug therapy</subject><subject>Histoplasmosis - microbiology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Intravitreal Injections</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ophthalmology</subject><subject>Prospective Studies</subject><subject>Receptors, Vascular Endothelial Growth Factor - administration & dosage</subject><subject>Recombinant Fusion Proteins - administration & dosage</subject><subject>Tomography, Optical Coherence</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity - physiology</subject><issn>0008-4182</issn><issn>1715-3360</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1TAUhC0EopfCC7BAXrJJ8LGT2JUQErriT6pgQWFr2c4JdZrEwXaK-vY4uoUFC1ZncWZGmm8IeQ6sBgbdq7Ee3RhqzqCtAWrG5ANyAAltJUTHHpIDY0xVDSh-Rp6kNDImhGy6x-SMS6Za3rUHcnMV0eQZl0zDQI-fv9OELiy9iXc0B7pGTNuMPQ1um0yk1z7lsE4mzSH5RH_5fE39kqO59bkETdQMk7cYHa6Z8prR-Uf5j-iyD8tT8mgwU8Jn9_ecfHv_7ur4sbr88uHT8e1l5RqAXA3OQM8MLx24QSuE5cpxNRirJEcQg1KStcL0FqxppbnombNWWtlzZdRwIc7Jy1PuGsPPDVPWs08Op8ksGLakQSrOoSsAipSfpC6GlCIOeo1-LuU1ML1D1qPeIesdsgbQBXIxvbjP32xh89fyh2oRvD4JsLS89Rh1ch4Xh72PBYXug_9__pt_7G7yi3dmusE7TGPY4lL4adCJa6a_7jPvK0PLWKOaTvwGoamkTA</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Walia, Harpreet S., MD</creator><creator>Shah, Gaurav K., MD</creator><creator>Blinder, Kevin J., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160401</creationdate><title>Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection</title><author>Walia, Harpreet S., MD ; Shah, Gaurav K., MD ; Blinder, Kevin J., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-fca1d0a23602aeb33b28c28fab872e13f887053adb1ba57a9d0cbb7b7d28a8f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - microbiology</topic><topic>Eye Infections, Fungal - drug therapy</topic><topic>Eye Infections, Fungal - microbiology</topic><topic>Female</topic><topic>Fluorescein Angiography</topic><topic>Histoplasmosis - drug therapy</topic><topic>Histoplasmosis - microbiology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Intravitreal Injections</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ophthalmology</topic><topic>Prospective Studies</topic><topic>Receptors, Vascular Endothelial Growth Factor - administration & dosage</topic><topic>Recombinant Fusion Proteins - administration & dosage</topic><topic>Tomography, Optical Coherence</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walia, Harpreet S., MD</creatorcontrib><creatorcontrib>Shah, Gaurav K., MD</creatorcontrib><creatorcontrib>Blinder, Kevin J., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walia, Harpreet S., MD</au><au>Shah, Gaurav K., MD</au><au>Blinder, Kevin J., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection</atitle><jtitle>Canadian journal of ophthalmology</jtitle><addtitle>Can J Ophthalmol</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>51</volume><issue>2</issue><spage>91</spage><epage>96</epage><pages>91-96</pages><issn>0008-4182</issn><eissn>1715-3360</eissn><abstract>Abstract Objective To assess the efficacy and safety of intravitreal aflibercept injection in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS). Purpose To assess safety of intravitreal aflibercept for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome. Methods Masked, open-label, prospective study. Five subjects will receive 2.0 mg aflibercept injection every 8 weeks with 3 initial monthly doses over a 12 month period. Results No adverse systemic or ocular were reported. At month six, the mean visual acuity improved by 7.8 ETDRS letters, mean central subfoveal thickness decreased by 38.8 microns and mean OCT volume decreased by 0.076 mm3 . At month twelve, the mean visual acuity improved by12.4 ETDRS letters, mean central subfoveal thickness decreased by 34.6 microns and mean OCT volume decreased by 0.576 mm3. Conclusion The use of intravitreal 2.0 mg aflibercept injection for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome yielded no systemic or ocular adverse events and produced improvement in visual acuity and reduction of OCT thickness and volume.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>27085265</pmid><doi>10.1016/j.jcjo.2015.11.007</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-4182 |
| ispartof | Canadian journal of ophthalmology, 2016-04, Vol.51 (2), p.91-96 |
| issn | 0008-4182 1715-3360 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1782216526 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Angiogenesis Inhibitors - administration & dosage Choroidal Neovascularization - drug therapy Choroidal Neovascularization - microbiology Eye Infections, Fungal - drug therapy Eye Infections, Fungal - microbiology Female Fluorescein Angiography Histoplasmosis - drug therapy Histoplasmosis - microbiology Humans Internal Medicine Intravitreal Injections Male Middle Aged Ophthalmology Prospective Studies Receptors, Vascular Endothelial Growth Factor - administration & dosage Recombinant Fusion Proteins - administration & dosage Tomography, Optical Coherence Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology |
| title | Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T14%3A21%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20CNV%20secondary%20to%20presumed%20ocular%20histoplasmosis%20with%20intravitreal%20aflibercept%202.0%20mg%20injection&rft.jtitle=Canadian%20journal%20of%20ophthalmology&rft.au=Walia,%20Harpreet%20S.,%20MD&rft.date=2016-04-01&rft.volume=51&rft.issue=2&rft.spage=91&rft.epage=96&rft.pages=91-96&rft.issn=0008-4182&rft.eissn=1715-3360&rft_id=info:doi/10.1016/j.jcjo.2015.11.007&rft_dat=%3Cproquest_cross%3E1782216526%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1782216526&rft_id=info:pmid/27085265&rft_els_id=S0008418215004846&rfr_iscdi=true |